MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling

Nature Communications

Volumn 4, Issue , 2013, Pages

  Yi, Jae Sung ^a   Park, Jun Sub ^a   Ham, Young Mi ^a   Nguyen, Nga ^a   Lee, Na Rae ^a   Hong, Jin ^a   Kim, Bong Woo ^a   Lee, Hyun ^a   Lee, Chang Seok ^a   Jeong, Byung Cheon ^a   Kyu Song, Hyun ^a   Cho, Hana ^a   Kim, Yoon Ki ^a   Lee, Jae Seon ^b   Park, Kyong Soo ^c   Shin, Haksub ^d   Choi, Inho ^d   Lee, Seung Hee ^e   Park, Woo Jin ^e   Park, Shi Young ^f   Choi, Cheol Soo ^f,g   Lin, Peihui ^h   Karunasiri, Malith ^h   Tan, Tao ^h   Duann, Pu ^h   Zhu, Hua ^h   Ma, Jianjie ^h   Ko, Young Gyu ^a   more..

^a Korea University   (South Korea)

^b Korea Institute of Radiation and Medical Science   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

^d Yonsei University Wonju   (South Korea)

^e Gwangju Institute of Science and Technology (GIST)   (South Korea)

^f Lee Gil Ya Cancer and Diabetes Institute   (South Korea)

^g Gachon University   (South Korea)

^h OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR SUBSTRATE 1; MITSUGUMIN 53; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

ENZYME ACTIVITY; HORMONE; MOLECULAR ANALYSIS; MUSCLE; SIGNALING; SKELETAL REMAINS;

ANIMAL CELL; ARTICLE; CONJUGATION; CONTROLLED STUDY; DIABETIC PATIENT; HUMAN; HUMAN TISSUE; IN VITRO STUDY; INSULIN RESISTANCE; MOUSE; MUSCULOSKELETAL DEVELOPMENT; NONHUMAN; PROTEIN EXPRESSION; RING FINGER MOTIF; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; UBIQUITINATION;

ANIMALS; CARRIER PROTEINS; CELL DIFFERENTIATION; CELL LINE; DIABETES MELLITUS; DIET, HIGH-FAT; GLUCOSE TOLERANCE TEST; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE DEVELOPMENT; MUSCLE, SKELETAL; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITINATION;

EID: 84883166199     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms3354     Document Type: Article

References (57)

1. Braun, T. & Gautel, M. Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat. Rev. Mol. Cell Biol. 12, 349-361 (2011).
2. Sandri, M. Signaling in muscle atrophy and hypertrophy. Physiology (Bethesda) 23, 160-170 (2008).
3. Baker, J., Liu, J. P., Robertson, E. J. & Efstratiadis, A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75, 73-82 (1993). (Pubitemid 23306022)
4. Liu, J. P., Baker, J., Perkins, A. S., Robertson, E. J. & Efstratiadis, A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75, 59-72 (1993). (Pubitemid 23306021)
5. Powell-Braxton, L. et al. IGF-I is required for normal embryonic growth in mice. Genes Dev. 7, 2609-2617 (1993). (Pubitemid 24021017)
6. Alzghoul, M. B., Gerrard, D., Watkins, B. A. & Hannon, K. Ectopic expression of IGF-I and Shh by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo. FASEB J. 18, 221-223 (2004).
7. Musaro, A. et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle. Nat. Genet. 27, 195-200 (2001). (Pubitemid 32157448)
8. Chambon, C. et al. Myocytic androgen receptor controls the strength but not the mass of limb muscles. Proc. Natl Acad. Sci. USA 107, 14327-14332 (2010).
9. Sainz, N. et al. Leptin administration favors muscle mass accretion by decreasing FoxO3a and increasing PGC-1alpha in ob/ob mice. PLoS One 4, e6808 (2009).
10. Gardner, S., Alzhanov, D., Knollman, P., Kuninger, D. & Rotwein, P. TGF-beta inhibits muscle differentiation by blocking autocrine signaling pathways initiated by IGF-II. Mol. Endocrinol. 25, 128-137 (2011).
11. Shimizu, N. et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab. 13, 170-182 (2011).
12. Glass, D. J. Signalling pathways that mediate skeletal muscle hypertrophy and atrophy. Nat. Cell Biol. 5, 87-90 (2003). (Pubitemid 36204186)
13. Glass, D. J. PI3 kinase regulation of skeletal muscle hypertrophy and atrophy. Curr. Top. Microbiol. Immunol. 346, 267-278 (2010).
14. Clemmons, D. R. Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol. Metab. 20, 349-356 (2009).
15. Otto, A. & Patel, K. Signalling and the control of skeletal muscle size. Exp. Cell Res. 316, 3059-3066 (2010).
16. Ohanna, M. et al. Atrophy of S6K1(-/-) skeletal muscle cells reveals distinct mTOR effectors for cell cycle and size control. Nat. Cell Biol. 7, 286-294 (2005).
17. Bodine, S. C. et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat. Cell Biol. 3, 1014-1019 (2001). (Pubitemid 34428747)
18. Hribal, M. L., Nakae, J., Kitamura, T., Shutter, J. R. & Accili, D. Regulation of insulin-like growth factor-dependent myoblast differentiation by Foxo forkhead transcription factors. J. Cell Biol. 162, 535-541 (2003). (Pubitemid 37022932)
19. Stitt, T. N. et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol. Cell. 14, 395-403 (2004). (Pubitemid 38591410)
20. Sandri, M. et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 117, 399-412 (2004). (Pubitemid 38534545)
21. Bodine, S. C. et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 294, 1704-1708 (2001). (Pubitemid 33104839)
22. Sacheck, J. M., Ohtsuka, A., McLary, S. C. & Goldberg, A. L. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am. J. Physiol. Endocrinol. Metab. 287, E591-601 (2004). (Pubitemid 39242684)
23. Potthoff, M. J., Olson, E. N. & Bassel-Duby, R. Skeletal muscle remodeling. Curr. Opin. Rheumatol. 19, 542-549 (2007). (Pubitemid 47530873)
24. Murton, A. J., Constantin, D. & Greenhaff, P. L. The involvement of the ubiquitin proteasome system in human skeletal muscle remodelling and atrophy. Biochim. Biophys. Acta. 1782, 730-743 2008.
25. Kawabe, H. & Brose, N. The role of ubiquitylation in nerve cell development. Nat. Rev. Neurosci. 12, 251-268 (2011).
26. Ozato, K., Shin, D. M., Chang, T. H. & Morse, 3rd H. C. TRIM family proteins and their emerging roles in innate immunity. Nat. Rev. Immunol. 8, 849-860 (2008).
27. Kim, B. W. et al. Lipid raft proteome reveals that oxidative phosphorylation system is associated with the plasma membrane. Expert. Rev. Proteomics. 7, 849-866 (2010).
28. Lee, C. S. et al. TRIM72 negatively regulates myogenesis via targeting insulin receptor substrate-1. Cell Death. Differ. 17, 1254-1265 (2010).
29. Jung, S. Y. & Ko, Y. G. TRIM72, a novel negative feedback regulator of myogenesis, is transcriptionally activated by the synergism of MyoD (or myogenin) and MEF2. Biochem. Biophys. Res. Commun. 396, 238-245 (2010).
30. Cai, C. et al. MG53 regulates membrane budding and exocytosis in muscle cells. J. Biol. Chem. 284, 3314-3322 (2009).
31. Cai, C. et al. MG53 nucleates assembly of cell membrane repair machinery. Nat. Cell Biol. 11, 56-64 (2009).
32. Zhu, H. et al. Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair. J. Biol. Chem. 286, 12820-12824 (2011).
33. Park, E. Y. et al. Crystal structure of PRY-SPRY domain of human TRIM72. Proteins 78, 790-795 (2010).
34. Rommel, C. et al. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt. Science 286, 1738-1741 (1999). (Pubitemid 129515881)
35. Murgia, M. et al. Ras is involved in nerve-activity-dependent regulation of muscle genes. Nat. Cell Biol. 2, 142-147 (2000).
36. Ye, Y. & Rape, M. Building ubiquitin chains: E2 enzymes at work. Nat. Rev. Mol. Cell Biol. 10, 755-764 (2009).
37. Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806 (2001). (Pubitemid 34000783)
38. Niu, W. et al. Maturation of the regulation of GLUT4 activity by p38 MAPK during L6 cell myogenesis. J. Biol. Chem. 278, 17953-17962 (2003). (Pubitemid 36799402)
39. Ueyama, A., Yaworsky, K. L., Wang, Q., Ebina, Y. & Klip, A. GLUT-4myc ectopic expression in L6 myoblasts generates a GLUT-4-specific pool conferring insulin sensitivity. Am. J. Physiol. 277, E572-578 (1999). (Pubitemid 29458219)
40. Mitsumoto, Y. & Klip, A. Development regulation of the subcellular distribution and glycosylation of GLUT1 and GLUT4 glucose transporters during myogenesis of L6 muscle cells. J. Biol. Chem. 267, 4957-4962 (1992).
41. Hotamisligil, G. S. Inflammation and metabolic disorders. Nature 444, 860-867 (2006). (Pubitemid 46024993)
42. Shoelson, S. E., Lee, J. & Goldfine, A. B. Inflammation and insulin resistance. J. Clin. Invest. 116, 1793-1801 (2006). (Pubitemid 44033299)
43. Lumeng, C. N. & Saltiel, A. R. Inflammatory links between obesity and metabolic disease. J. Clin. Invest. 121, 2111-2117 (2011).
44. Ouchi, N., Parker, J. L., Lugus, J. J. & Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85-97 (2011).
45. Serra, C. et al. Functional interdependence at the chromatin level between the MKK6/p38 and IGF1/PI3K/AKT pathways during muscle differentiation. Mol. Cell 28, 200-213 (2007). (Pubitemid 47599998)
46. Pete, G. et al. Postnatal growth responses to insulin-like growth factor I in insulin receptor substrate-1-deficient mice. Endocrinology 140, 5478-5487 (1999). (Pubitemid 30645334)
47. Tamemoto, H. et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372, 182-186 (1994). (Pubitemid 24347838)
48. Araki, E. et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372, 186-190 (1994). (Pubitemid 24347839)
49. Kawaguchi, T. et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am. J. Pathol. 165, 1499-1508 (2004). (Pubitemid 39435150)
50. Nakao, R. et al. Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol. Cell Biol. 29, 4798-4811 (2009).
51. Xu, X. et al. The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol. Cell 30, 403-414 (2008). (Pubitemid 351672370)
52. Shi, J., Luo, L., Eash, J., Ibebunjo, C. & Glass, D. J. The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling. Dev. Cell 21, 835-847 (2011).
53. Song, R. et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature 494, 375-379 (2013).
54. Shim, E. H. et al. Targeted disruption of hsp70.1 sensitizes to osmotic stress. EMBO Rep. 3, 857-861 (2002).
55. Yi, J. S. et al. Ginsenoside Rh2 induces ligand-independent Fas activation via lipid raft disruption. Biochem. Biophys. Res. Commun. 385, 154-159 (2009).
56. American Diabetes Association. Diabetes Care 33(Suppl. 1): S62-S69 (2010).
57. Weisleder, N. et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci. Transl. Med. 4, 139ra85 (2012).